Kalshi defends betting on drug trials

- Kalshi defended its drug-trial betting markets on August 5 after criticism intensified over contracts tied to cancer studies and other late-stage clinical outcomes. - Kalshi says traders can bet only after enrollment ends and that contracts resolve against named public documents, while critics call the model a “death market.” - The pilot launched with AppliedXL on July 16, and the contracts remain listed on Kalshi’s medicine-markets page.

Kalshi is defending a new line of prediction markets that lets users trade on whether late-stage clinical trials succeed and whether the U.S. Food and Drug Administration approves certain drugs. The company launched the pilot on July 16 with data partner AppliedXL, saying the markets would make drug-development probabilities public for the first time. Critics in medicine and bioethics have answered that the model turns life-and-death research into a tradable wager and could create new risks around insider access and patient trust. ### How do these contracts actually work? Kalshi said on July 16 that the pilot covers late-stage clinical trial outcomes and FDA regulatory decisions, not early-stage studies. The company said it will list a trial contract only after enrollment has finished, and each market is tied to a named public source such as a ClinicalTrials.gov primary endpoint, an FDA approval letter or an advisory committee vote record. (news.kalshi.com) Reuters reported that the launch included more than a dozen contracts, including wagers on FDA decisions involving Gilead’s experimental cancer drug anito-cel and Summit Therapeutics’ lung-cancer drug ivonescimab, as well as whether AriBio’s Alzheimer’s drug meets the main goals of a late-stage trial. Forbes separately reported that the initial markets were limited to Phase 3 trials run by established biopharma companies and full FDA approvals. (news.kalshi.com) ### What is Kalshi’s defense? Tarek Mansour, Kalshi’s chief executive, said in the company’s launch statement that drug development is “one of the most important and most information-constrained industries on earth” and that public contracts can surface information that is otherwise held privately by banks, expert networks and drug companies. Kalshi said the markets are intended to produce a “continuously updated” public probability based on evidence rather than company messaging. (money.usnews.com) Kalshi also said the exchange requires employment verification and bars trading by anyone with material nonpublic information. The company told Reuters that the contracts are structured so traders can take a view on a single drug outcome rather than on the whole company behind it. ### Why are patients and former regulators objecting? (news.kalshi.com) Robert Califf, the former FDA commissioner, told the New York Times, as quoted by Futurism, that “turning loose a betting market in an ongoing randomized clinical trial really is a breach of scientific conduct.” Futurism also cited concerns that a market betting against success could affect how trial participants view the study they are in. (money.usnews.com) Walter Ingaharro Jr., a metastatic pancreatic cancer patient, told the New York Times, as quoted by Futurism, “We’re literally trying to stay alive,” adding that “the introduction of gambling into the process really creates an ethical mess.” Joshua Pederson, a Boston University humanities professor whose son is in a cancer trial, wrote in the Guardian that Kalshi’s plan would let people bet on treatments tied to his son’s survival; Futurism quoted him asking, “How is this not just another type of ‘death market’?” (futurism.com) ### Where do the insider-trading and addiction concerns come from? MedCity News reported on July 21 that healthcare executives saw the contracts as vulnerable to insider trading because large late-stage trials involve many people with access to sensitive information, including statisticians, sponsor staff and site personnel. Shashi Shankar, chief executive of Novellia, told the publication that the model could “treat a patient’s illness like a coin flip.” (futurism.com) Connecticut Comptroller Sean Scanlon said this week that prediction markets have a “dark side,” citing insider trading, youth-targeted marketing and weak consumer protections in a state economic update reported by CT Mirror and posted by his office. Those warnings were not specific to drug-trial markets, but they add to the broader scrutiny around prediction-market platforms including Kalshi. (medcitynews.com) ### What happens next? Kalshi’s medicine-markets page remained live on August 6, showing the company is still offering contracts tied to treatments, trials and medical outcomes. The next concrete milestones are the named public documents built into each contract — trial readouts on ClinicalTrials.gov, FDA approval letters and advisory-committee vote records — which AppliedXL and Kalshi said will determine how the markets resolve. (kalshi.com) (ctmirror.org)

Get your own daily briefing

Scout delivers personalized news, insights, and conversations tailored to your role and industry.

Download on the App Store

Shared from Scout - Be the smartest in the room.